About Us
Your Partner in Medical Innovation





Founded in 2010, PT Revass Utama Medika is a premier distributor and marketing company specializing in interventional cardiology, peripheral vascular, neurovascular, aesthetic medicine, and more. Since its inception as the exclusive importer and distributor of stents and balloons from OrbusNeich Medical (Holding) B.V. in the Netherlands, PT Revass has steadily expanded its portfolio to include a comprehensive range of medical accessories that support cardiology interventions.


One Stop Solution Medical Devices Distributor
PT Revass Utama Medika is a leading medical equipment distributor in Indonesia, specializing in interventional cardiology, peripheral and neurovascular interventions, aesthetic medicine, and more. Since our founding in 2010, we have been committed to delivering premium-quality devices. Leveraging extensive industry expertise and a nationwide network, PT Revass continually provides tailored solutions that meet the evolving needs of healthcare professionals across Indonesia.
Leading The Innovation
Best Coverage Area
Professional Certification

I AM
Revassian
RE
Respect for People
VA
Perseverance
Strong individual and having determination to be the best.
SS
Customer Focus
Always provide best excellent services for customers.
I
Integrity
Engage to maintain consistency, accuracy, and trust.
AN
Collaboration
Synergize and collaborate.
Our Vision

Our Mission
- Become market leader of medical device distribution in Indonesia.
- Promoting high quality medical devices.
- Providing solutions of medical devices needs.
- Creating best place and pride company for employee.
- Provide an optimal investment for investors.
Meet Our Commissioner

Mr. David CHIEN (錢永勛)
Mr. David Chien (錢永勛) serves as Chairman, Executive Director and Chief Executive Officer of OrbusNeich. Since joining the company in February 2000, he has led its strategic planning and overseen the execution of corporate policies worldwide.
With more than 27 years of experience in the medical-device sector, Mr. Chien was Director of Cordis-Neich Limited from January 1994 to October 1997. He subsequently sat on the board of Tysan Holdings Limited (Stock Code: 0687) from November 1997 until January 2014. In addition, he has served as Trustee of the Chien Foundation since January 1997 and as Governor of KFoundation since July 2019. In 2020, he was elected to the Board of Trustees of Chung Chi College at The Chinese University of Hong Kong.
Mr. Chien completed his studies at York University in Canada.

Mr. David CHIEN (錢永勛)

Bachder
Mr. Bachder brings 17 years of finance expertise to his current roles. He began his career as Chief Financial Officer of PT WPP Group M, one of Indonesia’s largest media agencies, serving from 2006 to 2008. In 2010, he joined PT Bakrie Telecom Tbk as Head of Finance before moving later that year to PT Jatis Piranti Solusindo, an Indonesia Tbk subsidiary of Sumitomo Corporation specializing in IT and software consulting. Where he was Chief Financial Officer from 2010 to 2012. He then returned to PT Bakrie Telecom Tbk as CFO from April 2013 until 2015.
Since 2015, Mr. Bachder has founded and led several ventures across the information technology, telecommunications, and logistics sectors. Beginning in April 2016, he served as Financial Consultant, Investor, and Founder of the PT Kedung Group, comprising PT Kedung Artha Lumintu, KedungTranslog Lumintu, Kedung Media Lumintu, and Kedung Graha Lumintu — a position he holds to date. In April 2022, he also assumed the role of Finance Director at PT Seven Gates Indonesia Tbk, where he continues to drive financial strategy and performance.

Bachder
Meet Our Executive Director

Mr. Andriatno Martono
Mr. Andriatno Martono brings over 20 years of expertise in the pharmaceutical and medical-device sectors. He launched his career at PT Pfizer as a Medical Representative (1995–2001) before advancing to Product Manager for cardiovascular and neurology portfolios (2003–2007).
Later then, he joined PT Schering-Plough Indonesia as Product Manager overseeing cardiovascular, antibiotic, and anesthesia lines (2007–2011), followed by a similar role at PT Merck Sharp & Dohme Pharma Tbk in 2012. In addition to his product-management credentials, Mr. Martono has amassed more than 15 years of specialized experience in interventional cardiology.

Mr. Andriatno Martono

Ms. Kwai Ching Denise LAU (劉桂禎)
Ms. Kwai Ching Denise Lau (劉桂禎) is the Executive Director and Chief Operating Officer of OrbusNeich, where she leads and supervises all operational functions across the organization.
Ms. Lau brings over 21 years of legal, business-operations, and management experience to her role. She was admitted as a solicitor in Hong Kong in 1999 and subsequently qualified to practice in England and Wales (2000) and New York State (2001). From 2000 to 2006, she practised law as an attorney at Paul, Weiss, Rifkind, Wharton & Garrison. In February 2006, she joined Morgan Stanley, rising to Managing Director before departing in April 2015. Ms. Lau joined OrbusNeich on April 3, 2018, as General Counsel and was appointed Senior Vice President on the same date; she now serves as Executive Director and COO.
Ms. Lau earned her LL.B. (Bachelor of Laws) from The University of Hong Kong in 1996, followed by a Postgraduate Certificate in Laws (PCLL) in 1997. She holds an LL.M. in International Economic Law from the University of Warwick, which she completed in January 2001.

Ms. Kwai Ching Denise LAU (劉桂禎)

Mr. Wing Shing Jason CHEN (陳泳成)
Mr. Wing Shing Jason Chen (陳泳成) serves as Executive Director and Chief Financial Officer of OrbusNeich. With over 18 years of expertise in auditing, accounting, and corporate finance, he plays a pivotal role in shaping the company’s financial strategy and governance.
Mr. Chen began his career in December 2003 at PricewaterhouseCoopers in Hong Kong’s assurance practice, rising to Senior Manager by the time of his departure in February 2017. He then broadened his corporate-finance experience in mainland China’s property development and investment sector before joining OrbusNeich in April 2017 as Financial Controller. In January 2018, he was promoted to Chief Financial Officer, assuming full responsibility for the Group’s financial planning, reporting, and risk management.
He graduated with First-Class Honours in Business Administration—specializing in Financial Engineering—from The Chinese University of Hong Kong in December 2003. Mr. Chen is a Certified Public Accountant in Hong Kong, the State of Washington, and the State of Delaware, and he is also a CFA charterholder.

Mr. Wing Shing Jason CHEN (陳泳成)
Meet Our Senior Management

Kuncoro Nugroho
He began his career in 2007 in the automotive industry at PT Tri Mandiri Sejati as Chief of Accounting, where he quickly established himself by streamlining month-end close processes and ensuring accurate financial reporting. Over the next twelve years, he deepened his expertise in finance, accounting, and taxation across diverse sectors. From 2016 to 2019, he served as Finance, Accounting, and Tax Manager at PT Panca Jaya Setia, a Korean workshop equipment distributor where he led efforts to automate tax compliance and optimize working-capital management.
In 2020, he embraced a new challenge in the medical-device field as Finance, Accounting, and Tax Manager at PT Revass Utama Medika. There, he introduced a centralized expense-approval workflow and upgraded the ERP system, generating both cost savings and greater transparency. Recognizing his leadership and strategic vision, management promoted him to Head of Finance, Accounting, and Tax in 2022, and then to Finance and Distribution Director in 2024. In his current role, he oversees end-to-end financial operations—including distribution logistics—and continues to drive innovation in financial controls and performance management.

Kuncoro Nugroho

Satriyo Hermawan
Mr. Satriyo Hermawan began his sales career in 2009 as a Senior Product Specialist at Boston Scientific Indonesia, where he introduced and sold advanced medical devices, building a deep understanding of market needs and effective sales strategies. In 2010, he joined PT Dexa Medika, further refining his expertise in client relationship management and product promotion.
In 2012, he moved to PT Kalbe Farma, one of Indonesia’s largest pharmaceutical companies — where he honed his marketing and sales acumen and cultivated a robust professional network across the industry.
Leveraging this experience, he joined PT Revass Utama Medika in 2015 as Regional Sales Manager. In that role, he designed and executed targeted sales plans, driving significant growth in his territory and elevating team performance through coaching and process improvements. His achievements led to his appointment as National Sales Manager in 2021, where he oversaw nationwide sales operations, optimized distribution channels, and exceeded revenue targets.
In 2022, he was promoted to Head of Sales, and he currently serves as Sales Director. In this capacity, he leads the company’s entire sales organization, setting strategic direction, developing high-impact go-to-market initiatives, and maintaining strong partnerships with key accounts to sustain long-term growth.

Satriyo Hermawan

Aditya Bagus
Mr. Aditya Bagus began his career in 2010 in the banking industry as a Human Resources specialist at PT Bank BNI Syariah, ultimately rising to the role of HR Strategy and Policy Manager.
In 2017, he transitioned to PT Revass Utama Medika, a leading medical-device company, where he served as HR & GA Manager. In that capacity, he not only managed and developed the company’s human-resources function but also oversaw legal compliance, contract review, and licensing.
Recognized for his strategic insight and leadership, he was promoted to Head of HRGA in 2021 and most recently elevated to Operations Director in 2024, where he continues to drive operational excellence and organizational growth.

Aditya Bagus
Explore Key Achievements and Major Events in Our Journey

2010
- Establishment of PT Revass Utama Medika with less than 10 employees.
- Orbusneich became Sole Distributor for coronary vascular products.

2012
Revision of the Bill of Materials (BOM) composition.
Lepu Medical appointed as an authorized distributor of accessory products.
BenQ Medical appointed as an authorized distributor of accessory products.

2016
PT Revass Utama Medika was honored for its contributions to the ISICAM–InaLive 2016 event in Jakarta, themed “Optimizing Outcomes Through Innovations in Cardiovascular Intervention.”
PT Revass Utama Medika received the “Highest Worldwide Combo Sales” accolade from OrbusNeich.

2017
PT Revass has begun implementing Good Corporate Governance (GCG) practices.
Expanded its network to serve 105 hospitals nationwide.
PT Revass Utama Medika was honored with the Outstanding Performance Sales Award from OrbusNeich.
PT Revass Utama Medika received the “Highest Combo Sales in the World” accolade from OrbusNeich.

2018
Streamlined business processes across all functions, with a particular focus on enhancing managerial operations.
PT Revass Utama Medika was recognized for its participation in ISICAM–InaLive 2018, themed “A Journey of ISICAM: Driving Toward Excellence,” in Jakarta.

2019
Overhauled corporate management by implementing end-to-end digital processes.
Awarded “Highest Market Share Contribution to OrbusNeich in APAC (excluding Japan and China).”
Honored with the “Highest Global Combo Sales” accolade from OrbusNeich.

2020
Professionalization of corporate management through enhanced governance and best practices.
Company-wide digitization of all business processes via ERP implementation.
Successful implementation of CDAKB (Good Distribution Practice for Medical Devices) certification.
Expansion of our product portfolio with advanced solutions such as the Atherectomy System.

2021
Continued digitalization of all business processes through comprehensive ERP integration.
Achieved CDAKB certification and ISO 13485 accreditation for our Quality Management Systems.
Expanded our network to 223 hospital outlets nationwide.
Broadened our product portfolio with advanced congenital and peripheral vascular solutions.

2022
ISO 9001:2015 Certification
Critical Care Alliance: Partnered with PT Fresenius Medical Care Indonesia to distribute and support advanced critical care products.
Aesthetic Expansion: Entered the beauty and aesthetic market in collaboration with Ronas Korea, broadening our service portfolio.
MoU with PT Indofarma Tbk: Formalized a memorandum of understanding to explore joint opportunities in pharmaceutical development and distribution.
Tender Consolidation: Streamlined procurement processes by consolidating tenders, enhancing efficiency and cost-effectiveness.
Revassian Development Program: Launched an internal talent and leadership initiative to nurture future-ready professionals.

2023
Obtained ISO 37001:2016 Certification (Anti-Bribery Management System).
Established a partnership with Wego Medical for Neuro Vascular products.
Increased customer outlets to a total of 259 hospitals.
Acquired majority share ownership of 84% by OrbusNeich Medical Ltd.
PT Revass Utama Medika received the Highest Market Share Contribution to OrbusNeich in the APAC Territory (except Japan) award.
Received an award from Lepu Medical as Top Strategic Partner for Occluder.
Conducted Employee Incentive Trips to various countries in Europe.